You just read:

Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

News provided by

Janssen Research and Development LLC

Dec 03, 2016, 19:05 ET